105 related articles for article (PubMed ID: 16353248)
1. Expression of prothymosin alpha is correlated with development and progression in human prostate cancers.
Suzuki S; Takahashi S; Takahashi S; Takeshita K; Hikosaka A; Wakita T; Nishiyama N; Fujita T; Okamura T; Shirai T
Prostate; 2006 Apr; 66(5):463-9. PubMed ID: 16353248
[TBL] [Abstract][Full Text] [Related]
2. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
4. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
5. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells.
Asirvatham AJ; Schmidt MA; Chaudhary J
Prostate; 2006 Jun; 66(9):921-35. PubMed ID: 16541417
[TBL] [Abstract][Full Text] [Related]
6. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
7. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Wang JC; Bégin LR; Bérubé NG; Chevalier S; Aprikian AG; Gourdeau H; Chevrette M
Clin Cancer Res; 2007 Apr; 13(8):2354-61. PubMed ID: 17406028
[TBL] [Abstract][Full Text] [Related]
9. cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers.
Cantile M; Kisslinger A; Cindolo L; Schiavo G; D'Antò V; Franco R; Altieri V; Gallo A; Villacci A; Tramontano D; Cillo C
J Cell Physiol; 2005 Nov; 205(2):202-10. PubMed ID: 15895411
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma.
Jou YC; Tung CL; Tsai YS; Shen CH; Syue-Yi C; Shiau AL; Tsai HT; Wu CL; Tzai TS
Urology; 2009 Oct; 74(4):951-7. PubMed ID: 19679339
[TBL] [Abstract][Full Text] [Related]
11. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
[TBL] [Abstract][Full Text] [Related]
12. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer.
Wang J; Thompson B; Ren C; Ittmann M; Kwabi-Addo B
Prostate; 2006 May; 66(6):613-24. PubMed ID: 16388505
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
Wang M; Pan JY; Song GR; Chen HB; An LJ; Qu SX
Eur J Surg Oncol; 2007 Mar; 33(2):195-201. PubMed ID: 17046193
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
15. Loss of uteroglobin expression in prostate cancer: relationship to advancing grade.
Weeraratna AT; Cajigas JA; Schwartz A; Enquist EG; Manyak MJ; Patierno SR
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2295-300. PubMed ID: 9815627
[TBL] [Abstract][Full Text] [Related]
16. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
17. Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
[TBL] [Abstract][Full Text] [Related]
18. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
Casimiro M; Rodriguez O; Pootrakul L; Aventian M; Lushina N; Cromelin C; Ferzli G; Johnson K; Fricke S; Diba F; Kallakury B; Ohanyerenwa C; Chen M; Ostrowski M; Hung MC; Rabbani SA; Datar R; Cote R; Pestell R; Albanese C
Cancer Res; 2007 May; 67(9):4364-72. PubMed ID: 17483350
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profile of prostate cancer cell lines: effect of nerve growth factor treatment.
Sigala S; Bodei S; Missale C; Zani D; Simeone C; Cunico SC; Spano PF
Mol Cell Endocrinol; 2008 Mar; 284(1-2):11-20. PubMed ID: 18280641
[TBL] [Abstract][Full Text] [Related]
20. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 Aug; 67(11):1143-51. PubMed ID: 17503471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
